More on SNY
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $46.06 |
|
|||
| Open | $46.21 | ||||
| 52 Wk High | $44.76 | ||||
| 52 Wk Low | $36.81 | ||||
| Day High | $46.48 | ||||
| Day Low | $46.12 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,334,125 | ||||
- Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alon
- Will this be the next obesity stock to be acquired?
- JPMorgan Downgrades Sanofi (SAN:FP) (SNY) to Neutral
- Form 6-K Sanofi For: Dec 01
- Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
- Sanofi (SNY) Said To Work With Rothschild On OTC Spinoff Preparations - Bloomberg
- Sanofi-Aventis (SNY) PT Raised to $56 at Berenberg
- Eli Lilly, Novo Nordisk drop as UnitedHealth lowers Insulin costs
- French Financial Prosecutor is Examining Sanofi over Possible Share Price Manipulation - Reuters
- Sanofi (SAN:FP) (SNY) PT Lowered to EUR92 at JPMorgan
Entities mentioned with SNY
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- JPMorgan | View Related Stories »
- PDUFA | View Related Stories »
- Warren Buffett | View Related Stories »
- Show More...
